{"url_path":"/sec/coo/8-k/2026-06-04/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-04","source_url":"https://www.sec.gov/Archives/edgar/data/711404/0001628280-26-040823-index.html","accession_number":"0001628280-26-040823","cik":"0000711404","ticker":"COO","issuer_name":"COOPER COMPANIES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/711404/0001628280-26-040823-index.html","primary_entity_key":"0000711404","primary_entity_name":"COOPER COMPANIES, INC."},"word_count":281,"has_tables":true,"body_markdown":"ITEM 8.01. Other Events.\n\nAs described in its June 4, 2026 press release, the Company recorded a charge as further described below.\n\nIn December 2023, CooperSurgical, one of the Company’s two business units, initiated a voluntary recall of three specific lots of CooperSurgical’s LifeGlobalTM global® embryo culture media that it had produced. Subsequently, claims and lawsuits in various U.S. and international jurisdictions were brought by individuals who generally allege that they suffered damages associated with the use of the recalled product, including claims of embryo loss or reduced embryo viability. As of June 4, 2026, more than 140 lawsuits were filed, including three putative class actions (none of which has been certified), and over 1,500 claimants have been proffered to the Company.\n\nBetween December 2023 and mid-March 2026, the Company resolved a significant number of claims and lawsuits through settlements which were largely covered by insurance. From mid-March 2026, the Company identified developments, including the procedural acceleration of multiple litigated cases, receipt of additional claimant information, updated damage valuation analysis, and significantly increased projected defense and expert costs, which resulted in a reassessment of exposure. The Company proceeded with negotiations and has reached settlement agreements covering over 95% of claimants. Based on this, management concluded that a loss was probable and reasonably estimable, particularly with respect to potential exposure exceeding available insurance coverage. The net impact to the consolidated statements of operations to resolve outstanding claims was $271.6 million, consisting of $324.1 million accrued litigation liabilities, partially offset by $52.5 million of expected insurance recoveries. The net amount was recorded within Selling, General and Administrative expenses. The Company currently expects the majority of the payments to be made during fiscal 2026."}